See more : Swire Pacific Limited (SWRAF) Income Statement Analysis – Financial Results
Complete financial analysis of Astria Therapeutics, Inc. (ATXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Astria Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hellenic Telecommunications Organization S.A. (HLTOY) Income Statement Analysis – Financial Results
- Spineway SA (ALSPW.PA) Income Statement Analysis – Financial Results
- Luceco plc (LUCE.L) Income Statement Analysis – Financial Results
- Paxman AB (publ) (PXMBF) Income Statement Analysis – Financial Results
- Modern Cinema Group, Inc. (MOCI) Income Statement Analysis – Financial Results
Astria Therapeutics, Inc. (ATXS)
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 26.00K | 119.00K | 0.00 | 395.00K | 202.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -26.00K | -119.00K | 500.00K | -395.00K | -202.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 57.33M | 34.26M | 15.55M | 25.59M | 18.32M | 17.04M | 18.68M | 25.45M | 23.03M | 15.69M | 13.99M | 12.41K |
| General & Administrative | 25.70M | 19.24M | 14.81M | 11.85M | 8.77M | 9.33M | 8.91M | 10.11M | 8.63M | 6.00M | 4.13M | 3.27K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 718.00 |
| SG&A | 25.70M | 19.24M | 14.81M | 11.85M | 8.77M | 9.33M | 8.91M | 10.11M | 8.63M | 6.00M | 4.13M | 3.98K |
| Other Expenses | 0.00 | -55.00K | -58.00K | -101.00K | -50.00K | 176.00K | 32.00K | 93.00K | 7.00K | 3.00K | 1.00K | 0.00 |
| Operating Expenses | 83.03M | 53.50M | 30.36M | 37.44M | 27.09M | 26.37M | 27.59M | 35.56M | 31.66M | 21.68M | 18.12M | 15.67K |
| Cost & Expenses | 83.03M | 53.50M | 30.36M | 37.44M | 27.09M | 26.37M | 27.59M | 35.56M | 31.66M | 21.68M | 18.12M | 15.67K |
| Interest Income | 10.20M | 1.72M | 122.00K | 236.00K | 845.00K | 425.00K | 160.00K | 242.00K | 0.00 | 0.00 | 0.00 | 4.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 462.00K | 837.00K | 978.00K | 206.00K | 0.00 | 0.00 |
| Depreciation & Amortization | -15.20M | 228.49K | -164.62M | 26.00K | 26.00K | 119.00K | 304.00K | 395.00K | 202.00K | 248.00K | 320.00K | 327.00 |
| EBITDA | -83.03M | -53.50M | -194.98M | -37.44M | -26.27M | -25.65M | -26.60M | -34.83M | -31.46M | -21.43M | -17.80M | -15.34M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,319.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -83.03M | -53.50M | -194.98M | -37.44M | -27.09M | -26.37M | -27.09M | -35.56M | -31.66M | -21.68M | -18.12M | -15.67K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,418.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.14M | 1.67M | 64.00K | 135.00K | 795.00K | 501.00K | -270.00K | -502.00K | -971.00K | -203.00K | 1.00K | 4.00 |
| Income Before Tax | -72.89M | -51.83M | -194.91M | -37.30M | -26.29M | -25.87M | -27.36M | -36.06M | -32.63M | -21.88M | -18.12M | -15.67K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,472.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.67M | -164.74M | -236.00K | -50.00K | 601.00K | 494.00K | 930.00K | 783.00K | 209.00K | 0.00 | 0.00 |
| Net Income | -72.89M | -50.17M | -30.17M | -37.06M | -26.24M | -25.87M | -27.36M | -36.06M | -32.63M | -21.88M | -18.12M | -15.67K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,472.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.42 | -3.43 | -3.38 | -12.12 | -14.06 | -30.71 | -75.73 | -133.31 | -243.45 | -151.53 | -125.45 | -0.11 |
| EPS Diluted | -2.42 | -3.43 | -3.38 | -12.12 | -14.06 | -30.71 | -75.73 | -133.31 | -243.45 | -151.53 | -125.45 | -0.11 |
| Weighted Avg Shares Out | 30.12M | 14.62M | 8.93M | 3.06M | 1.87M | 842.47K | 361.36K | 270.50K | 134.03K | 144.42K | 144.42K | 144.42K |
| Weighted Avg Shares Out (Dil) | 30.12M | 14.62M | 8.93M | 3.06M | 1.87M | 842.47K | 361.36K | 270.50K | 134.03K | 144.42K | 144.42K | 144.42K |
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 21,000 shares of Astria's common stock on February 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan....
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the pricing of an underwritten offering of 10,340,000 shares of its...
Here's What Insiders Are Buying to Wrap Up the Year
As the year wound to a close, biotechs were in focus among the notable insider purchases.
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 52,000 shares of Astria's common stock on December 1, 2023 under Astria's 2022 Inducement Stock Incentive Plan....
Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share STAR-0215 Phase 1a results in an encore presentation at the annual World Allergy Congress on Sunday,...
Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and information on STAR-0215 and STAR-0310 at...
Astria Therapeutics, Inc. (ATXS) Q3 2023 Earnings Call Transcript
Astria Therapeutics, Inc. (NASDAQ:ATXS ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Elizabeth Higgins - Investor Relations Jill Milne - Co Founder, CEO, President & Director Noah Clauser - CFO & Treasurer Christopher Morabito...
Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update. “We are...
Is a Surprise Coming for Astria Therapeutics (ATXS) This Earnings Season?
Astria Therapeutics (ATXS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, is presenting new STAR-0215 data in a poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) in Anaheim, California...
Source: https://incomestatements.info
Category: Stock Reports